CAR-T Platform

Healthy T cells and malignant T cells share the same surface proteins (target antigens)

Deletion of the target antigen from the surface of the engineered CAR-T cell, that is derived from a healthy donor T cell, prevents self-killing (fratricide) while ensuring CAR-T cells kill malignant T cells

Deletion of the T-cell receptor (TCR) enables the use of T cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD)

Next in our story